Grafting peptides onto polystyrene microplates for ELISA

Niveleau, Alain; Bruno, C.; Drouet, Emmanuel; Brebant, R.; Sergeant, Alain; Troalen, Frédéric

doi:10.1016/0022-1759(95)00053-d

Cited by 21 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Usually peptides do not have the same conformation free in solution as when adsorbed or covalently coupled to microtiter plates, the orientation of an immobilized antigen being important for recognition by an antibody. A strategy to overcome the low coating efficiency of highly hydrophilic peptides to microtiter plates and to avoid unpredictable orientation of the peptides on the surface is based on the covalent attachment of the synthetic peptides to the immunoassay surfaces [30][31][32][33][34][35][36]. Covalent binding, unlike simple physical binding, may orientate the immobilized peptides in a defined way on the solid phase.…”

Section: Chemical Derivatization Of Synthetic Peptidesmentioning

confidence: 99%

Synthetic Peptides for the Immunodiagnosis of Human Diseases

Gómara¹,

Haro

2007

CMC

View full text Add to dashboard Cite

Synthetic peptides have been shown to be valuable tools for viral laboratory diagnosis and can provide uniform, chemically well-defined antigens for antibody analysis, reducing inter- and intra-assay variation. The main aim in the development of peptide-based diagnostic tests is to recognise specific antibodies induced by the whole viral proteins but using selected short fragments containing the most potent antigenic determinants. The success of this approach depends on the extent to which synthetic peptides are able to mimic the immunodominant epitopes of antigens. In recent years, synthetic peptides that mimic specific epitopes of infectious agents' proteins have been used in diagnostic systems for various human diseases. The present review summarizes some of the drawbacks of the use of relatively short linear peptides as antigenic substrates and the subsequent chemical strategies developed in order to overcome the low peptide reactivity against specific antibodies. Moreover, it outlines the most significant bibliography published in the last five years which provides validated peptide based tests potentially useful for diagnosis of viral, bacterial, parasitic and autoimmune diseases.

show abstract

Section: Chemical Derivatization Of Synthetic Peptidesmentioning

confidence: 99%

Synthetic Peptides for the Immunodiagnosis of Human Diseases

Gómara¹,

Haro

2007

CMC

View full text Add to dashboard Cite

show abstract

“…The detection limits of various methods reported so far are as follows: 0.1-50 ng proteins/ml in sandwich ELISA (12); 10 g lipids/ml (13); 25-30 ng DNAs/ml (3); Alcian blue-coated plates gave results 1000 times more sensitive than conventional ELISA (4); and 0.1-500 pmol peptides in fluorescence-based ELISA (14). The detection limits of 0.1-1 fmol peptide obtained by HMDA plates in this study are much higher than those described above.…”

Section: Figmentioning

confidence: 99%

Immobilization of Saccharides and Peptides on 96-Well Microtiter Plates Coated with Methyl Vinyl Ether–Maleic Anhydride Copolymer

Satoh

Kojima

Koyama

et al. 1998

Analytical Biochemistry

View full text Add to dashboard Cite

“…ZEBRA, highly immunogenic, elicits robust T-cell responses [10,[67][68][69][70][71][72] that dominate the early immune responses in patients [70]. B-cell epitopes were additionally described; to illustrate, the DNA-binding domain of ZEBRA (basic region, including the so-called RAK epitope) is a major target antigen for IgM antibody response in EBV primary infection (45), whereas the N-terminus part (activation domain) is mainly recognized by IgG in patients with EBV reactivation [35,[73][74][75].…”

Section: The Role Of Some Lytic Ebv Proteins In the Tumorigenesis Andmentioning

confidence: 99%

The Role of the Epstein-Barr Virus Lytic Cycle in Tumor Progression: Consequences in Diagnosis and Therapy

Drouet¹

2020

Human Herpesvirus Infection - Biological Features, Transmission, Symptoms, Diagnosis and Treatment

View full text Add to dashboard Cite

The Epstein-Barr virus (EBV) reactivation corresponds to the activation of EBV global replication involving not only the origin of the latent viral replication but also that of the origin of lytic replication. During this reactivation, a minority of B cells infected with EBV in its latent form enter the lytic phase. During this phase, all EBV proteins are produced, enabling the assembly of complete virions that lysate their host cells and infect neighboring cells (lytic cycle). This horizontal EBV transmission seeks to increase the pool of EBV-infected B cells. This chapter seeks to review the role of the lytic EBV proteins (particularly that of the ZEBRA protein) in tumor development. This protein is the main transcription factor of EBV, expressed during the activation of the lytic cycle. Recently, we demonstrated that this immediate early protein can be detected in the soluble state (s-ZEBRA) in the serum of patients with posttransplant lymphoproliferative disorder. We highlighted the role of ZEBRA in EBV pathogenesis in transplanted subjects, not only as a key protein in the activation of EBV replication but also as a protein "toxoid" released into the extracellular milieu. This release could result in increased secretion of immunomodulatory cytokines and that of angiogenesis-promoting factors conducive to tumor progression.

show abstract

Grafting peptides onto polystyrene microplates for ELISA

Cited by 21 publications

References 11 publications

Synthetic Peptides for the Immunodiagnosis of Human Diseases

Synthetic Peptides for the Immunodiagnosis of Human Diseases

Immobilization of Saccharides and Peptides on 96-Well Microtiter Plates Coated with Methyl Vinyl Ether–Maleic Anhydride Copolymer

The Role of the Epstein-Barr Virus Lytic Cycle in Tumor Progression: Consequences in Diagnosis and Therapy

Contact Info

Product

Resources

About